Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Homology Medicines stock price, quote, forecast and news

QTTB
US4380831077
A2JGTY

Price

36.23
Today +/-
+0
Today %
+0 %
P

Homology Medicines Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Homology Medicines, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Homology Medicines from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Homology Medicines’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Homology Medicines. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Homology Medicines’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Homology Medicines’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Homology Medicines’s growth potential.

Homology Medicines Revenue, EBIT and net profit per share

DateHomology Medicines RevenueHomology Medicines EBITHomology Medicines Net Income
2026e0 undefined-107.89 M undefined-63.53 M undefined
2025e0 undefined-71.4 M undefined-55.9 M undefined
2024e0 undefined-56.95 M undefined-47.78 M undefined
20231.16 M undefined-92.1 M undefined-112.96 M undefined
20223.21 M undefined-133.28 M undefined-5.01 M undefined
202133.97 M undefined-95.95 M undefined-95.76 M undefined
20202.7 M undefined-130.26 M undefined-128.69 M undefined
20191.67 M undefined-109.94 M undefined-103.92 M undefined
20185.32 M undefined-59.93 M undefined-55.58 M undefined
20170 undefined-29.66 M undefined-29.99 M undefined
20160 undefined-10 M undefined-8.05 M undefined

Homology Medicines Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e
005123331000
----80.00100.001,550.00-90.91-66.67---
-----------
00000000000
-10-29-59-109-130-95-133-92-56-71-107
---1,180.00-10,900.00-6,500.00-287.88-4,433.33-9,200.00---
-8-29-55-103-128-95-5-112-47-55-63
-262.5089.6687.2724.27-25.78-94.742,140.00-58.0417.0214.55
36.0833.7528.5542.1245.9155.2857.43.21000
-----------
Details

Keystats

ⓘ

Revenue and Growth

The Homology Medicines Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Homology Medicines is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Homology Medicines provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Homology Medicines's financial health and stability.

Assets

Homology Medicines's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Homology Medicines must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Homology Medicines after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Homology Medicines's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-8-29-57-103-128-95-5-112
00167810
00000000
03412011-413-7
-11151419-11323
00000000
00000000
-86-42-91-94-109-113-96
-1-1-24-21-3-2-10
-2-81-121-51204-5036101
0-79-96-29208-4838101
00000000
00000000
0115150158535200
0115150158535200
--------
00000000
-1040-1315163-108-765
-10.474.52-67.5-113.19-98.06-112.15-114.95-96.46
00000000

Homology Medicines stock margins

The Homology Medicines margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Homology Medicines. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Homology Medicines.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Homology Medicines's sales revenue. A higher gross margin percentage indicates that the Homology Medicines retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Homology Medicines's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Homology Medicines's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Homology Medicines's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Homology Medicines. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Homology Medicines's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Homology Medicines Margin History

Homology Medicines Gross marginHomology Medicines Profit marginHomology Medicines EBIT marginHomology Medicines Profit margin
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %-7,967.3 %-9,771.71 %
20220 %-4,152.03 %-156.07 %
20210 %-282.46 %-281.9 %
20200 %-4,824.44 %-4,766.3 %
20190 %-6,583.23 %-6,222.75 %
20180 %-1,126.5 %-1,044.74 %
20170 %0 %0 %
20160 %0 %0 %

Homology Medicines Stock Sales Revenue, EBIT, Earnings per Share

The Homology Medicines earnings per share therefore indicates how much revenue Homology Medicines has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Homology Medicines earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Homology Medicines's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Homology Medicines’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Homology Medicines's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Homology Medicines Revenue, EBIT and net profit per share

DateHomology Medicines Sales per ShareHomology Medicines EBIT per shareHomology Medicines Earnings per Share
2026e0 undefined0 undefined-5.32 undefined
2025e0 undefined0 undefined-4.68 undefined
2024e0 undefined0 undefined-4 undefined
20230.36 undefined-28.66 undefined-35.16 undefined
20220.06 undefined-2.32 undefined-0.09 undefined
20210.61 undefined-1.74 undefined-1.73 undefined
20200.06 undefined-2.84 undefined-2.8 undefined
20190.04 undefined-2.61 undefined-2.47 undefined
20180.19 undefined-2.1 undefined-1.95 undefined
20170 undefined-0.88 undefined-0.89 undefined
20160 undefined-0.28 undefined-0.22 undefined

Homology Medicines business model

Homology Medicines Inc. is a US-based company focused on the development of gene therapy technologies. The company was founded in 2015 and is headquartered in Bedford, Massachusetts. Homology Medicines Inc. aims to develop and market innovative gene therapies for rare diseases and genetic disorders. The company's goal is to develop new therapies through gene editing that can specifically modify genes to treat or alleviate symptoms of diseases. Homology Medicines bases its methodology on the natural processes of viral transport, through which double-stranded DNA is anchored into the cell. This allows the DNA to be directly introduced into living tissue, where it has systemic effects. Homology's gene therapy technology is based on the recombination of adenoviral vectors. The business model of Homology Medicines is to develop and market innovative gene therapies for rare diseases and genetic disorders. The company focuses on close collaboration with clinics to make the new therapies quickly and efficiently available to patients. The company has a close partnership with the National Institute of Health (NIH) to utilize its technology for gene therapy of rare diseases and genetic disorders. Homology Medicines Inc. specializes in three different branches of gene therapy: 1. In vivo gene therapy: In this method, gene therapies are directly introduced into the patient's tissue. Homology Medicines is working on developing new efficient methods for virus transport of therapeutics into the central nervous system and cardiovascular tissue. These methods aim to minimize the occurrence of unwanted effects. 2. Ex vivo gene therapy: In ex vivo gene therapy, a patient's cells are taken, modified, and then reintroduced into the patient. This method is particularly relevant for immune system disorders and cancer treatments. Homology Medicines is working on new efficient methods for the transport of modifiers into cells. 3. Genome editing therapy: In this final branch, Homology Medicines is working on developing genome editors that are specifically designed for defective genes. The technology is intended for the treatment of genetic diseases and restoring the functionality of defective genes. Homology Medicines Inc. is known for its low costs in gene therapy development. By utilizing natural viral transport methods and closely analyzing defects in humans, the company is able to quickly and cost-effectively develop therapies for patients. The company has already initiated several successful developments in gene therapy and continues to seek new innovations and developments to better meet the needs of patients. Homology Medicines is one of the most popular companies on Eulerpool.com.

Homology Medicines SWOT Analysis

Strengths

Homology Medicines Inc possesses several strengths that contribute to its success in the market. Firstly, the company has a strong and experienced management team with extensive knowledge in the biopharmaceutical industry. This provides them with the capabilities to make informed strategic decisions and navigate the competitive landscape effectively.

Secondly, Homology Medicines has a robust portfolio of proprietary gene therapy technology. This technology enables the development of innovative treatments for genetic diseases with high precision and accuracy, giving the company a competitive edge in the market.

Furthermore, the company has established strategic partnerships with leading research institutions, which helps facilitate research and development activities, as well as provides access to a diverse pool of expertise.

Weaknesses

One of the weaknesses faced by Homology Medicines Inc is its relatively limited product pipeline. While the company's gene therapy technology is highly promising, it may take time to develop and commercialize new therapies, resulting in potential revenue gaps in the short to medium term.

Additionally, as a relatively smaller biopharmaceutical company, Homology Medicines Inc may face challenges in competing against larger, well-established competitors. Limited financial resources and marketing capabilities could hinder their ability to effectively promote and commercialize their products.

Opportunities

The field of gene therapy presents significant opportunities for Homology Medicines Inc. With advancements in technology and increasing acceptance of gene therapies, there is a growing demand for innovative treatments targeting genetic diseases. Homology Medicines can leverage its proprietary gene therapy platform to address unmet medical needs and capture a substantial market share.

Furthermore, the company can explore partnerships and collaborations with pharmaceutical companies to accelerate the development and commercialization of its therapies. Such collaborations can provide access to additional resources and expertise, as well as expanded distribution networks.

Threats

One of the main threats faced by Homology Medicines Inc is the evolving regulatory landscape. Changes in regulations pertaining to gene therapy and genetic modification could impact the company's ability to conduct research, obtain approvals, and market their products.

Moreover, the biopharmaceutical industry is highly competitive, with numerous companies investing in gene therapy research and development. Homology Medicines Inc may face intense competition from both established players and emerging startups in the sector.

Homology Medicines historical P/E ratio, EBIT, and P/S ratio.

Homology Medicines shares outstanding

The number of shares was Homology Medicines in 2023 — This indicates how many shares 3.213 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Homology Medicines earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Homology Medicines's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Homology Medicines’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Homology Medicines's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Homology Medicines.

Homology Medicines latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-2.37 -14.95  (-530.85 %)2024 Q1
12/31/2023-5.51 -5.04  (8.5 %)2023 Q4
9/30/2023-7.71 -10.26  (-33.05 %)2023 Q3
6/30/2023-8.72 -10.98  (-25.9 %)2023 Q2
3/31/2023-0.54 -0.5  (7.51 %)2023 Q1
12/31/2022-0.51 -0.6  (-16.78 %)2022 Q4
9/30/2022-0.48 -0.59  (-22.41 %)2022 Q3
6/30/2022-0.57 -0.51  (9.97 %)2022 Q2
3/31/2022-0.36 -0.2  (43.98 %)2022 Q1
12/31/2021-0.6 -0.59  (2.33 %)2021 Q4
1
2
3

Eulerpool ESG Scorecard© for the Homology Medicines stock

Eulerpool World ESG Rating (EESG©)

50/ 100

🌱 Environment

51

👫 Social

72

🏛️ Governance

28

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Homology Medicines list of shareholders

%
Name
Stocks
Change
Date
9.24 % Abingworth Management Limited1,102,7411,102,7413/26/2024
6.73 % Acorn Bioventures L.P.803,425803,4253/26/2024
2.68 % ARCH Venture Partners320,48302/5/2024
2.63 % Temasek Holdings Pte. Ltd.313,944012/31/2023
2.33 % Pfizer Inc277,77802/5/2024
2.11 % 5AM Ventures251,996012/31/2023
18.87 % OrbiMed Advisors, LLC2,252,9872,252,9873/28/2024
17.52 % Atlas Venture2,092,1062,092,1063/26/2024
1.45 % Adar1 Capital Management LLC173,379157,0643/4/2024
0.90 % The Vanguard Group, Inc.107,755-5,93612/31/2023
1
2
3
4
5
...
10

Homology Medicines Executives and Management Board

Dr. Arthur Tzianabos60
Homology Medicines Executive Chairman of the Board
Compensation 1.67 M
Dr. Albert Seymour55
Homology Medicines President, Chief Executive Officer, Director (since 2016)
Compensation 1.2 M
Mr. W. Bradford Smith67
Homology Medicines Chief Financial Officer, Treasurer, Chief Business Officer
Compensation 994,251
Dr. Paul Alloway52
Homology Medicines President, Chief Operating Officer, Company Secretary
Compensation 868,639
Ms. Mary Thistle63
Homology Medicines Independent Director
Compensation 76,064
1
2
3

Most common questions regarding Homology Medicines

What values and corporate philosophy does Homology Medicines represent?

Homology Medicines Inc represents values of innovation, integrity, and patient-centeredness. Their corporate philosophy revolves around developing groundbreaking genetic medicines to address serious rare diseases. Homology Medicines Inc is driven by a commitment to transform patients' lives by leveraging their proprietary platform technology, delivering precise, long-lasting genomic therapies. Their team of experts focuses on advancing gene therapy research and development, while upholding the highest standards of scientific excellence and ethical conduct. The company emphasizes collaboration with healthcare professionals, academia, and patient communities to ensure their therapies meet the unmet needs of patients worldwide.

In which countries and regions is Homology Medicines primarily present?

Homology Medicines Inc is primarily present in the United States.

What significant milestones has the company Homology Medicines achieved?

Some significant milestones achieved by Homology Medicines Inc include successful completion of Phase 1/2 pheNIX clinical trial for HMI-102 gene therapy in adults with phenylketonuria (PKU), initiation of Phase 1/2 pheNIX trial in pediatric PKU patients, and clearance of an Investigational New Drug (IND) application for HMI-103 gene therapy to treat metachromatic leukodystrophy (MLD). Furthermore, Homology Medicines has successfully developed an efficient and proprietary platform called AAVHSCs (adeno-associated virus vectors with human hematopoietic stem cells), which enables gene editing in hematopoietic stem cells. These achievements demonstrate the company's commitment to developing innovative gene therapies to address genetic diseases effectively, positioning Homology Medicines as a key player in the field.

What is the history and background of the company Homology Medicines?

Homology Medicines Inc is a biotechnology company focused on the development of genetic medicines. Established in 2015, Homology Medicines leverages its proprietary platform called AAVHSC (adeno-associated virus with homology-dependent DNA repair in mammalian cells) to treat rare genetic diseases. The company aims to provide transformative therapies for patients by harnessing the natural DNA repair process in the body. With a strong emphasis on gene editing and gene therapy technologies, Homology Medicines strives to address significant unmet medical needs. Through its research and development efforts, the company aims to pave the way for innovative genetic therapies that potentially offer long-term and durable solutions for patients in need.

Who are the main competitors of Homology Medicines in the market?

The main competitors of Homology Medicines Inc in the market include companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics.

In which industries is Homology Medicines primarily active?

Homology Medicines Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Homology Medicines?

The business model of Homology Medicines Inc is focused on developing and commercializing genetic medicines for patients with rare genetic diseases. The company utilizes its proprietary platform technology, called AAVHSCs (adeno-associated virus vectors derived from human hematopoietic stem cells), to deliver genetic therapies to treat a wide range of disorders. Homology Medicines aims to bring innovative treatments to patients by leveraging its expertise in gene editing, gene therapy, and gene delivery. Through strategic partnerships and collaborations, the company aims to accelerate the development and delivery of potentially transformative medicines to address unmet medical needs in the rare disease community.

What is the P/E ratio of Homology Medicines 2024?

The Homology Medicines P/E ratio is -2.44.

What is the P/S ratio of Homology Medicines 2024?

The Homology Medicines P/S ratio is 0.

What is the AlleAktien quality score of Homology Medicines?

The AlleAktien quality score for Homology Medicines is 1/10.

What is the revenue of Homology Medicines 2024?

The revenue cannot currently be calculated for Homology Medicines.

How high is the profit of Homology Medicines 2024?

The expected Homology Medicines profit is -47.78 M USD.

What is the business model of Homology Medicines

Homology Medicines Inc is a biopharmaceutical company focused on the development of gene therapies. The company's business model is based on the use of a proprietary gene therapy platform called AAVHSC (adeno-associated virus-human synthetic chromosome), which enables the transfer of genes to dissolve genetic diseases. The company operates in three main areas: research and development, production, and marketing. Homology's research and development arm focuses on the discovery and development of new gene therapies. The company has several programs in the pipeline that focus on various genetic diseases, including phenylketonuria (PKU) and metachromatic leukodystrophy (MLD). The goal is to develop a safe and effective treatment for patients with these diseases. Homology's production department includes the manufacturing of gene therapies using the AAVHSC technology, production of antibodies, and manufacturing of other biopharmaceutical products. The company has comprehensive production and manufacturing capacity to meet the demand for gene therapies. Homology's marketing department focuses on the marketing of gene therapies once they are approved. The company works closely with physicians, hospitals, and healthcare organizations to ensure that gene therapy is available to the right patients. The company also plans to develop offerings for the treatment of genetic diseases in collaboration with government agencies and healthcare providers. Homology differentiates itself from other gene therapy companies with its AAVHSC platform, which enables effective and safe gene therapy for a variety of genetic diseases. The platform also allows Homology to manufacture gene therapeutics for a larger patient population than other gene therapy companies. Additionally, Homology's broad range of products makes the company attractive to investors. Homology's gene therapies will operate in a rapidly growing industry as gene therapies prove useful for a variety of diseases. Furthermore, gene therapy appears to be a very profitable sector as the high costs of production and delivery of gene therapeutics provide a high return for companies. Due to its proprietary technology and broad product range, Homology has a strong position in the gene therapeutics market. Overall, Homology Medicines Inc's successful business model is based on its commitment to developing safe and effective gene therapies. The company is well-positioned to be successful in this growing sector and meet the needs of affected patients and their families.

What is the Homology Medicines dividend?

Homology Medicines pays a dividend of 0 USD distributed over payouts per year.

How often does Homology Medicines pay dividends?

The dividend cannot currently be calculated for Homology Medicines or the company does not pay out a dividend.

What is the Homology Medicines ISIN?

The ISIN of Homology Medicines is US4380831077.

What is the Homology Medicines WKN?

The WKN of Homology Medicines is A2JGTY.

What is the Homology Medicines ticker?

The ticker of Homology Medicines is QTTB.

How much dividend does Homology Medicines pay?

Over the past 12 months, Homology Medicines paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Homology Medicines is expected to pay a dividend of 0 USD.

What is the dividend yield of Homology Medicines?

The current dividend yield of Homology Medicines is .

When does Homology Medicines pay dividends?

Homology Medicines pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Homology Medicines?

Homology Medicines paid dividends every year for the past 0 years.

What is the dividend of Homology Medicines?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Homology Medicines located?

Homology Medicines is assigned to the 'Health' sector.

Wann musste ich die Aktien von Homology Medicines kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Homology Medicines from 7/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/27/2024.

When did Homology Medicines pay the last dividend?

The last dividend was paid out on 7/27/2024.

What was the dividend of Homology Medicines in the year 2023?

In the year 2023, Homology Medicines distributed 0 USD as dividends.

In which currency does Homology Medicines pay out the dividend?

The dividends of Homology Medicines are distributed in USD.

All fundamentals about Homology Medicines

Our stock analysis for Homology Medicines Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Homology Medicines Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.